Recent studies show that MSC-1 LIF blockade is safe and well tolerated in patients with advanced solid tumors and point to LIF as a as a novel drug target in immune-oncology
VIEW MORERecent studies show that MSC-1 LIF blockade is safe and well tolerated in patients with advanced solid tumors and point to LIF as a as a novel drug target in immune-oncology
VIEW MORESABCS 2022: POSITIVE study shows that interruption of endocrine therapy in breast cancer patients planning pregnancy does not result in worse short-term disease relapse
VIEW MORENext-generation SERD camizestrant significantly improves progression-free survival vs. fulvestrant in advanced ER+ HER2- breast cancer
Latest News
15 December 2022
Recent studies show that MSC-1 LIF blockade is safe and well tolerated in patients with advanced solid tumors and point to LIF as a as a novel drug target in immune-oncology
Published in ESMO Open, results of a phase I first-in-human study co-authored by investigators at the Vall d’Hebron Institute of...
08 December 2022
SABCS 2022: POSITIVE study shows that interruption of endocrine therapy in breast cancer patients planning pregnancy does not result in worse short-term disease relapse
Presented at the 45th annual San Antonio Breast Cancer Symposium® (2022 SABCS®), primary results of the multicenter international POSITIVE study...
08 December 2022
Next-generation SERD camizestrant significantly improves progression-free survival vs. fulvestrant in advanced ER+ HER2- breast cancer
Presented today (1) at the 45th annual San Antonio Breast Cancer Symposium® (2022 SABCS®), results of the phase II SERENA-2...
25 November 2022
Under the review spotlight: current insights into the molecular bases of gastric cancer, targeted treatment strategies in the pipeline, and future therapeutic opportunities
Recently published in Nature Reviews Gastroenterology & Hepatology*, a comprehensive Review focused on gastric cancer and gastro-oesophageal junction cancer (GC-GOJC)...
Research Programs
PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group
Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group
We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).
CORE TECHNOLOGIES
Cancer Genomics Group
VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.
PRINCIPAL RESEARCHERS
Events
Thursday 15 December 22 - 11:00 AM
Patients
Maternity and cancer: how to face the disease during pregnancy, postpartum and raising of our children
Thursday 15 December 22 - 04:00 PM
scientific-seminars
Bruno Di Stefano | Dissecting mechanisms that govern cellular identity
Thursday 15 December 22 - 11:00 AM
Patients
How to learn to love yourself after cancer. Emotional management tools. Workshop 1
Thursday 15 December 22 - 04:00 PM
scientific-seminars
Bruno Di Stefano I Defining the Role of RNA Sequestration in Oncogenesis
